INNOVENT BIO (01801.HK) Chief Research Officer Qian Lei recently outlined the company’s ambitious growth plans during a media event co-hosted with JD HEALTH (06618.HK). "INNOVENT BIO currently has 16 marketed products, making it the Chinese biopharma leader in monoclonal antibody therapies. Our innovations have benefited 5 million patients, supported by 21 clinical pipelines, 14,000 liters of operational capacity, 30+ global partnerships, and 7,500 employees," Qian stated.

By 2025, INNOVENT aims to commercialize 17 products and achieve positive EBITDA. The three-year target for 2027 includes 20 marketed products generating RMB 20 billion in revenue. By 2030, the company plans to advance five pipelines into global Phase III trials, positioning itself as a top-tier international biopharma firm serving patients in China, the U.S., Japan, and Europe.

Addressing the societal focus on weight management, Qian highlighted INNOVENT’s breakthrough drug Mazdutide (Xinermei®), the first China-developed GLP-1/GCG dual-target obesity treatment approved on June 27. Within a week of its July launch, Mazdutide debuted on JD HEALTH’s platform, attracting over 30,000 users in its first month. Searches for "Xinermei" on JD surpassed 1 million between July 4 and August 4.

The strategic partnership between INNOVENT and JD HEALTH, formalized in July, spans supply chain optimization, omnichannel sales, and digital marketing. Yang Jingyu, INNOVENT’s Senior Director of Commercial Innovation, cited JD HEALTH’s strengths: a robust cold-chain logistics network for temperature-sensitive biologics, a vast user base aligned with metabolic drug demographics, and data-driven precision marketing.

JD HEALTH’s Li Yanping emphasized patient safety in weight management, noting the March launch of an online "Weight Management Clinic" with multidisciplinary support, including endocrinologists and nutritionists. The platform’s 10,000+ licensed pharmacists and AI assistant "Xiaofang" have handled 300,000 consultations this year, issuing 12,000 medication risk alerts.

With 33 pharmaceutical warehouses nationwide, JD HEALTH ensures same- or next-day delivery for 90% of orders across 400 cities. For GLP-1 drugs requiring 2–8°C storage, its urban cold-chain service delivers in as fast as two hours, while "Instant Delivery" achieves nine-minute turnarounds.

At JD Logistics’ Kunshan pharmaceutical warehouse near INNOVENT’s Suzhou HQ, specialized cold-chain equipment maintains 2–8°C for 72 hours, ensuring drug integrity during transport.

Looking ahead, INNOVENT plans to deepen collaboration with JD HEALTH, leveraging digital tools to integrate precision therapy with long-term patient management.